Details of the Drug
General Information of Drug (ID: DMG6ZU4)
Drug Name |
Lanreotide acetate
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Lanreotide; Angiopeptin acetate; Somatuline; Somatulin; 127984-74-1; DC 13-116; Autogel; 108736-35-2; BIM 23014; Bim-23014; Lanreotide [INN:BAN]; Lanreotidum [INN-Latin]; Lanreotida [INN-Spanish]; Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2; 10-(4-Aminobutyl)-19-[(2-amino-3-naphthalen-2-yl-propanoyl)amino]-N-(1 -carbamoyl-2-hydroxy-propyl)-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol -3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14, 17-pentazacycloicosane-4-carboxamide; Somatuline lp (TN); Lanreotide Autogel
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 4 | Molecular Weight (mw) | 1096.3 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 2.5 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 17 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 13 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 14 | |||||||||||||||||||
ADMET Property | ||||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Acromegaly | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | 5A60.0 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Disease Different from Lanreotide acetate (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90. | ||||
---|---|---|---|---|---|
2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2031). | ||||
3 | Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Drugs Today (Barc). 2013 Feb;49(2):89-103. | ||||
4 | An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9. | ||||
5 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
6 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356). | ||||
7 | Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31. | ||||
8 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | ||||
9 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | ||||
10 | Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. | ||||
11 | TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101. | ||||
12 | The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5. | ||||
13 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
14 | Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34. | ||||
15 | Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52. | ||||
16 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
17 | Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ. | ||||
18 | Cerner Multum, Inc. "Australian Product Information.". | ||||
19 | Product Information. Lutathera (lutetium Lu 177 dotatate). Advanced Accelerator Applications, New York, NY. | ||||
20 | Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ. | ||||
21 | Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA. | ||||
22 | Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
23 | Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA. | ||||
24 | Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA. | ||||
25 | Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE. | ||||
26 | Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA. | ||||
27 | Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA. | ||||
28 | Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA. | ||||
29 | Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ. | ||||
30 | Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL. | ||||